Study identification

PURI

https://redirect.ema.europa.eu/resource/1000000012

EU PAS number

EUPAS1000000012

Study ID

1000000012

Official title and acronym

id.DRIVE surveillance study of respiratory pathogens in adults hospitalised for severe acute respiratory infection (SARI) across Europe

DARWIN EU® study

No

Study countries

Belgium
Germany
Italy
Spain

Study description

id.DRIVE’s Study Network will be leveraged to continuously monitor severe acute respiratory infection (SARI)-causing pathogens (e.g., severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza, and respiratory syncytial virus [RSV]), including virological and clinical trends, as well as burden of disease (e.g., pathogen-specific morbidity; in-hospital mortality).
The surveillance of additional pathogens allows for study preparedness, with the potential to perform feasibility assessments for future impact and effectiveness studies within the id.DRIVE Study Network.

Study status

Planned
Research institution and networks

Institutions

P95 Epidemiology & Pharmacovigilance
Belgium
Colombia
Netherlands
South Africa
Thailand
United States
First published:
09/04/2024
Institution
Laboratory/Research/Testing facilityNon-Pharmaceutical companyENCePP partner
Valencia Hospital Surveillance Network for the Study of Influenza and Other Infectious Diseases (VAHNSI)
Le Centre Hospitalier Universitaire St Pierre (CHU St Pierre)
Universitair Ziekenhuis Antwerpen (UZA)
Centro Interuniversitario per la Ricerca sull’Influenza e le altre Infezioni Trasmissibili (CIRI-IT)
Hospital Universitario Germans Trias i Pujol (GTPUH)
Hospital Clínic de Barcelona
Hospital Clínico Universitario de Santiago de Compostela
Universitätsklinikum Freiburg
Universitätsklinikum Frankfurt
Universitätsklinikum Ulm
Ospedale Luigi Sacco

Networks

id.DRIVE (former COVIDRIVE)
Austria
Belgium
Croatia
Czechia
Denmark
France
Germany
Iceland
Italy
Poland
Romania
Spain
First published:
29/02/2024
Network
ENCePP partner

Contact details

Kaatje Bollaerts

Primary lead investigator
Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

AstraZeneca, Pfizer
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable